Caffeine-containing products (e.g., Excedrin Migraine)

Excedrin Migraine and Regular Excedrin contain identical active ingredients (250mg acetaminophen, 250mg aspirin, 65mg caffeine) with the primary difference being FDA-approved labeling for migraine-specific relief. Research shows caffeine increases bioavailability and effectiveness of both acetaminophen and aspirin by up to 40% and provides vasoconstriction benefits for headache relief.

Study findings indicate that caffeine-containing combination products like Excedrin Migraine should be the first choice of OTC drug in migraine patients and are associated with better therapeutic results compared to other OTC drugs, though more than half of migraine patients using OTC drugs did not achieve adequate pain freedom within 2 hours due to inappropriate use.

Clinical evidence demonstrates that while not first-line therapy according to current guidelines, the acetaminophen, aspirin, and caffeine combination shows efficacy for migraine treatment with 59.3% of patients achieving mild or no pain at 2 hours compared to 32.8% placebo, and 50.8% pain-free at 6 hours versus 23.5% placebo.

Three double-blind, placebo-controlled trials involving 1,220 migraineurs demonstrated that the acetaminophen, aspirin, and caffeine combination significantly reduced migraine pain intensity from 1 to 6 hours post-dose, with 59.3% achieving mild or no pain at 2 hours versus 32.8% placebo, and 50.8% pain-free at 6 hours versus 23.5% placebo. Associated symptoms including nausea, photophobia, phonophobia, and functional disability were also significantly improved.

This systematic review confirmed the efficacy of caffeine as an analgesic adjuvant in acute migraine treatment, documenting that the acetaminophen, aspirin, and caffeine combination (AAC-130) achieved 21% pain-free rates at 2 hours versus 7% placebo and 51% pain-free at 6 hours versus 24% placebo, with headache response rates of 59% versus 33% at 2 hours.

Three double-blind, placebo-controlled trials involving 1,220 migraineurs demonstrated that the acetaminophen, aspirin, and caffeine combination significantly reduced migraine pain intensity from 1 to 6 hours post-dose, with 59.3% achieving mild or no pain at 2 hours versus 32.8% placebo, and 50.8% pain-free at 6 hours versus 23.5% placebo. Associated symptoms including nausea, photophobia, phonophobia, and functional disability were also significantly improved.

This systematic review confirmed the efficacy of caffeine as an analgesic adjuvant in acute migraine treatment, documenting that the acetaminophen, aspirin, and caffeine combination (AAC-130) achieved 21% pain-free rates at 2 hours versus 7% placebo and 51% pain-free at 6 hours versus 24% placebo, with headache response rates of 59% versus 33% at 2 hours.

Excedrin Migraine and Regular Excedrin contain identical active ingredients (250mg acetaminophen, 250mg aspirin, 65mg caffeine) with the primary difference being FDA-approved labeling for migraine-specific relief. Research shows caffeine increases bioavailability and effectiveness of both acetaminophen and aspirin by up to 40% and provides vasoconstriction benefits for headache relief.

Excedrin Migraine and Regular Excedrin contain identical active ingredients (250mg acetaminophen, 250mg aspirin, 65mg caffeine) with the primary difference being FDA-approved labeling for migraine-specific relief. Research shows caffeine increases bioavailability and effectiveness of both acetaminophen and aspirin by up to 40% and provides vasoconstriction benefits for headache relief.